Novo Nordisk allies with Bluebird Bio to develop gene therapies
Novo Nordisk has started to collaborate with the American superstar biotech company Bluebird Bio to develop gene therapies for hemophilia and other genetic diseases.
Novo Nordisk is ramping up its efforts in the biopharma area with a brand-new development collaboration with one of this year’s most talked-about biotech companies, Blue Bird Bio.
Allerede abonnent?Log ind her
Læs hele artiklen
Få adgang i 14 dage for 0 kr. Det kræver intet kreditkort, og du vil ikke overgå til et betalt abonnement efterfølgende.
